2017
DOI: 10.1093/rheumatology/kew431
|View full text |Cite
|
Sign up to set email alerts
|

Type I interferon–mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
106
0
14

Year Published

2018
2018
2023
2023

Publication Types

Select...
5
2

Relationship

3
4

Authors

Journals

citations
Cited by 121 publications
(121 citation statements)
references
References 140 publications
1
106
0
14
Order By: Relevance
“…cells have a role in many autoimmune diseases and their measurement has potential to stratify outcomes and use of therapies, but previous studies yielded conflicting results (33).…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…cells have a role in many autoimmune diseases and their measurement has potential to stratify outcomes and use of therapies, but previous studies yielded conflicting results (33).…”
Section: Discussionmentioning
confidence: 99%
“…Predictors of a severe disease trajectory or flares are needed to achieve this. Response to conventional and targeted therapies in SLE and related diseases is variable and re-classification of autoimmune diseases according to pathogenic mechanisms instead of clinical features has been proposed (33).…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…The type I interferon (IFN) response, where one side is first-line of defense against invading pathogens (esp. viruses), on the other side, its uncontrolled activation can lead to several autoimmune diseases (Crow et al, 2019;Di Domizio and Cao, 2013;Psarras et al, 2017). A fine homeostatic balance of type I interferons needs to be maintained to avoid autoimmune diseases, including interferonopathies (Crow et al, 2019;Di Domizio and Cao, 2013;Lee-Kirsch et al, 2016;Niewold, 2014).…”
Section: Introductionmentioning
confidence: 99%